Clinical Experience with Perampanel in the Pediatric Population in two Canadian Centers
The purpose of this study is to describe the efficacy, tolerability and side effects of Perampanel in pediatric patients with refractory epilepsy. To do so, a retrospective detailed chart review of eligible patients at BCCH will be completed.

Impact of Pediatric Epilepsy Surgery on Health-Related Quality Of Life
The objective of this study is to evaluate the effectiveness of two treatments, epilepsy surgery relative to medical therapy, on improving health related quality of life (HRQL) longitudinally. The surgical group will be compared to a medical treatment group which has undergone work-up for surgery but deemed unsuitable for surgery. These two groups have been shown to have similar baseline characteristics. Outcome will be addressed using a novel comprehensive model that acknowledges a number of variables such as clinical status (seizure control), patient factors (mood and self-concept) and family factors (caregivers’ mood, family adaptation, resources and demands) can affect changes in HRQL.

A three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizures
The main purpose of this study is to find out if the drug everolimus (Afinitor®) is safe and has helpful effects in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizures. These are seizures that involve some type of body movement and are not adequately responding to ongoing treatment with epilepsy drugs. Many patients with TSC develop seizures. We are not sure if the seizures are caused by growth of certain cells in the brain or by changes in the way cells in the brain work together. Studies in animals that have changes in their brain similar to those seen with TSC, have demonstrated that seizures can be reduced by use of the everolimus.